{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:30:31Z","timestamp":1786984231220,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"33","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,14]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Platinum plus etoposide combined with programmed death-ligand 1 (PD-L1) inhibitors is the standard first-line therapy for patients with advanced small-cell lung cancer (SCLC). However, reliable prognostic biomarkers are yet to be identified. The lactate dehydrogenase-to-lymphocyte ratio (LLR) is a potential indicator of tumor metabolism and host immune response; a high LLR is correlated with a poor prognosis in other carcinomas. The LLR may be a more comprehensive indicator of prognosis than the neutrophil-lymphocyte ratio (NLR) or platelet-lymphocyte ratio (PLR), which mainly reflect host immune status. This study evaluates the prognostic value of the LLR in patients with SCLC receiving first-line chemoimmunotherapy. This retrospective, two-center study was conducted at 2 university hospitals in Japan and analyzed 64 patients with extensive-stage SCLC or post-chemoradiotherapy recurrence of limited-stage SCLC who received platinum-etoposide plus a PD-L1 inhibitor as first-line therapy between August 2019 and December 2023. The LLR, NLR, and PLR were calculated from blood tests immediately before the start of first-line therapy, and cutoff values were set using the X-tile software. The prognostic significance of these markers was assessed using Kaplan\u2013Meier survival analysis and the Cox proportional hazards model. Of the 64 patients included, 10 (16%) had high LLR (&gt;471.5). The median duration of observation was 10.5 months (interquartile range: 6.0\u201319.0 months); by the time of data cutoff, 56 patients (87.5%) had experienced progressive disease and 36 (56.3%) had died. The high LLR group had significantly shorter overall survival (OS) and progression-free survival (PFS). Multivariate analysis was performed using only those factors (LLR\/ECOG PS\/bone metastasis regarding OS and LLR\/bone metastasis regarding PFS) identified as significant in univariate analyses. A high LLR was an independent predictor of worse OS and PFS. While the NLR was an independent prognostic factor for OS, neither NLR nor PLR was a significant predictor of PFS. The LLR is a novel potential prognostic biomarker that integrates tumor metabolism and host immunity in patients with SCLC receiving first-line chemoimmunotherapy. Because it can be readily calculated from routine blood tests, it may serve as a cost-effective tool for risk stratification. However, further prospective validation in larger cohorts is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050249","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:02:07Z","timestamp":1786730527000},"page":"e50249","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Lactate dehydrogenase-to-lymphocyte ratio predicts overall and progression-free survival among patients with advanced small-cell lung cancer receiving first-line chemoimmunotherapy"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9251-7692","authenticated-orcid":false,"given":"Tomofumi","family":"Hirose","sequence":"first","affiliation":[{"name":"Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2365-144X","authenticated-orcid":false,"given":"Shuhei","family":"Teranishi","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Kanagawa Cancer Center, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Yokohama City University School of Medicine, Yokohama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihito","family":"Kajita","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Yokohama City University School of Medicine, Yokohama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayami","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Yokohama City University School of Medicine, Yokohama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kudo","sequence":"additional","affiliation":[{"name":"Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, Yokohama City University School of Medicine, Yokohama, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260817","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13578-024-01283-9","article-title":"Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer.","volume":"14","author":"Chen","year":"2024","journal-title":"Cell Biosci"},{"key":"R2-20260817","first-page":"7","article-title":"Cancer statistics, 2022.","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"R3-20260817","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2005.04.8595","article-title":"Randomized phase III trial comparing irinotecan\/cisplatin with etoposide\/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.","volume":"24","author":"Hanna","year":"2006","journal-title":"J Clin Oncol"},{"key":"R4-20260817","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer.","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"R5-20260817","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"R6-20260817","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3390\/cancers13020236","article-title":"Small-cell lung cancer: is the black box finally opening up?","volume":"13","author":"Hiddinga","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R7-20260817","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer.","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R8-20260817","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors.","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R9-20260817","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/bjc.2011.189","article-title":"The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis.","volume":"105","author":"Gooden","year":"2011","journal-title":"Br J Cancer"},{"key":"R10-20260817","first-page":"100544","article-title":"Real-world analysis of clinical characteristics and survival outcomes in patients with extensive-stage SCLC treated with first-line chemoimmunotherapy.","volume":"4","author":"Wang","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"R11-20260817","doi-asserted-by":"crossref","first-page":"e33432","DOI":"10.1097\/MD.0000000000033432","article-title":"Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy.","volume":"102","author":"Kutlu","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"R12-20260817","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1002\/cam4.1820","article-title":"Lactate dehydrogenase A: a key player in carcinogenesis and potential target in cancer therapy.","volume":"7","author":"Feng","year":"2018","journal-title":"Cancer Med"},{"key":"R13-20260817","doi-asserted-by":"crossref","first-page":"23111","DOI":"10.1074\/jbc.M202487200","article-title":"Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis.","volume":"277","author":"Lu","year":"2002","journal-title":"J Biol Chem"},{"key":"R14-20260817","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature13490","article-title":"Functional polarization of tumour-associated macrophages by tumour-derived lactic acid.","volume":"513","author":"Colegio","year":"2014","journal-title":"Nature"},{"key":"R15-20260817","doi-asserted-by":"crossref","first-page":"23620","DOI":"10.18632\/oncotarget.25306","article-title":"A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival.","volume":"9","author":"Keane","year":"2018","journal-title":"Oncotarget"},{"key":"R16-20260817","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s12253-019-00707-z","article-title":"Lactate dehydrogenase-to-lymphocyte ratio represents a powerful prognostic tool of metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.","volume":"26","author":"Li","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"R17-20260817","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R18-20260817","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","article-title":"X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.","volume":"10","author":"Camp","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R19-20260817","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics.","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"R20-20260817","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1111\/1759-7714.13581","article-title":"Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.","volume":"12","author":"He","year":"2021","journal-title":"Thorac Cancer"},{"key":"R21-20260817","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2478\/raon-2020-0054","article-title":"Neutrophil-to-lymphocyte ratio can predict outcome in extensive-stage small cell lung cancer.","volume":"54","author":"Drpa","year":"2020","journal-title":"Radiol Oncol"},{"key":"R22-20260817","doi-asserted-by":"crossref","first-page":"8927","DOI":"10.1158\/0008-5472.CAN-06-1501","article-title":"Cancer\u2019s molecular sweet tooth and the Warburg effect.","volume":"66","author":"Kim","year":"2006","journal-title":"Cancer Res"},{"key":"R23-20260817","doi-asserted-by":"crossref","first-page":"697865","DOI":"10.3389\/fonc.2021.697865","article-title":"Prognostic value of the pretreatment lung immune prognostic index in advanced small cell lung cancer patients treated with first-line PD-1\/PD-L1 inhibitors plus chemotherapy.","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"R24-20260817","doi-asserted-by":"crossref","first-page":"696147","DOI":"10.3389\/fonc.2021.696147","article-title":"A novel prognostic marker for primary CNS lymphoma: lactate dehydrogenase-to-lymphocyte ratio improves stratification of patients within the low and intermediate MSKCC risk groups.","volume":"11","author":"Gao","year":"2021","journal-title":"Front Oncol"},{"key":"R25-20260817","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41598-024-84890-3","article-title":"Pretreatment neutrophil-to-lymphocyte ratio is associated with immunotherapy efficacy in patients with advanced cancer: a systematic review and meta-analysis.","volume":"15","author":"Su","year":"2025","journal-title":"Sci Rep"},{"key":"R26-20260817","doi-asserted-by":"crossref","first-page":"1490590","DOI":"10.3389\/fimmu.2024.1490590","article-title":"Advances in biomarkers for immunotherapy in small-cell lung cancer.","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:00:50Z","timestamp":1786982450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050249"}},"subtitle":["A two-center retrospective observational study"],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":26,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050249","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"2025-10-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}